Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Company Data

Name Regencell Bioscience Holdings Limited - Ordinary Shares

Company Regencell Bioscience Holdings Limited

Symbol RGC

Website https://www.regencellbioscience.com

Primary Exchange

NASDAQ

ISIN KYG7487R1002

Asset Class Share

Sector Healthcare

Industry Drug Manufacturers - Specialty & Generic

CEO Yat-Gai Au

Market Capitalization 7 Mrd.

Country Hong Kong

Currency USD

Employees 0,0 T

Address First Commercial Building, KY1-1107 Causeway Bay

IPO Date 2021-07-16

Stock Splits

Date	Split
16.06.2025	38:1

Ticker Symbols

Name	Symbol
NASDAQ	RGC

More Shares

Investors who hold Regencell Bioscience Holdings Limited - Ordinary Shares also have the following shares in their portfolio:

CARPINTERO FINANCE LIMITED 2.004% GRNTD NTS 18/09/24 Bond

LBBW FESTZINS 22/28 Bond

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog